UroGen Pharma Ltd.
URGN
$24.38
-$4.08-14.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.00% | 10.85% | 8.98% | 9.29% | 15.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.00% | 10.85% | 8.98% | 9.29% | 15.64% |
| Cost of Revenue | 33.73% | 25.48% | 7.47% | -5.13% | -6.88% |
| Gross Profit | 5.23% | 9.21% | 9.15% | 11.13% | 18.74% |
| SG&A Expenses | 34.88% | 35.89% | 32.91% | 28.71% | 22.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.19% | 31.58% | 29.44% | 25.52% | 16.58% |
| Operating Income | -58.01% | -53.68% | -54.35% | -46.00% | -17.59% |
| Income Before Tax | -45.18% | -37.55% | -34.77% | -26.16% | -6.71% |
| Income Tax Expenses | -25.64% | 5.33% | -19.81% | -27.76% | 434.70% |
| Earnings from Continuing Operations | -42.70% | -36.43% | -32.70% | -24.09% | -9.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.70% | -36.43% | -32.70% | -24.09% | -9.78% |
| EBIT | -58.01% | -53.68% | -54.35% | -46.00% | -17.59% |
| EBITDA | -57.42% | -54.42% | -55.54% | -47.30% | -18.36% |
| EPS Basic | -18.50% | -5.87% | 7.40% | 19.44% | 31.32% |
| Normalized Basic EPS | -20.07% | -5.99% | 7.05% | 19.32% | 33.42% |
| EPS Diluted | -18.50% | -5.87% | 7.40% | 19.44% | 31.32% |
| Normalized Diluted EPS | -20.07% | -5.99% | 7.05% | 19.32% | 33.42% |
| Average Basic Shares Outstanding | 18.54% | 29.42% | 40.91% | 48.77% | 57.15% |
| Average Diluted Shares Outstanding | 18.54% | 29.42% | 40.91% | 48.77% | 57.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |